Skip to content

Study · Non-randomized trial · 2018

6 results

Teriparatide Administration Increases Periprosthetic Bone Mineral Density After Total Knee Arthroplasty: A Prospective Study.

Suzuki T, Sukezaki F, Shibuki T, Toyoshima Y, Nagai T, Inagaki K

The Journal of arthroplasty25 Jul 2017Cited by 39 (Europe PMC)

PMID28869116 (opens in a new tab)DOI10.1016/j.arth.2017.07.026 (opens in a new tab)PepBankPUB-28869116
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients after knee arthroplasty, teriparatide increased adjusted posterior condyle BMD relative to controls at 6 months.

    In plain wordsIn patients after knee replacement, teriparatide increased posterior condyle bone density compared with controls at 6 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePosterior condyle BMD at 6 months
    Study

    n: not reported in source

    Comparator
    TKA control group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    As a result of adjusting the difference between the BMDs of the 2 groups at initiation, there was a significant increase in R3 (posterior condyle) and R4 (lateral) at 6 months.
    1 context sentence
    Summary · context
    Twenty-two knees in 17 patients were included in this study, and a control group of patients who underwent TKA was identified according to their medical records.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients after knee arthroplasty, teriparatide increased adjusted lateral region BMD relative to controls at 6 months.

    In plain wordsIn patients after knee replacement, teriparatide increased lateral bone density compared with controls at 6 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLateral region BMD at 6 months
    Study

    n: not reported in source

    Comparator
    TKA control group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    As a result of adjusting the difference between the BMDs of the 2 groups at initiation, there was a significant increase in R3 (posterior condyle) and R4 (lateral) at 6 months.
    1 context sentence
    Summary · context
    Twenty-two knees in 17 patients were included in this study, and a control group of patients who underwent TKA was identified according to their medical records.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients after knee arthroplasty, teriparatide increased adjusted anterior condyle BMD relative to controls at 12 months.

    In plain wordsIn patients after knee replacement, teriparatide increased anterior condyle bone density compared with controls at 12 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseAnterior condyle BMD at 12 months
    Study

    n: not reported in source

    Comparator
    TKA control group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, there was a significant increase in R2 (anterior condyle), R3 (posterior condyle), and R6 (tibial diaphysis) at 12 months.
    1 context sentence
    Summary · context
    Twenty-two knees in 17 patients were included in this study, and a control group of patients who underwent TKA was identified according to their medical records.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients after knee arthroplasty, teriparatide increased adjusted posterior condyle BMD relative to controls at 12 months.

    In plain wordsIn patients after knee replacement, teriparatide increased posterior condyle bone density compared with controls at 12 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePosterior condyle BMD at 12 months
    Study

    n: not reported in source

    Comparator
    TKA control group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, there was a significant increase in R2 (anterior condyle), R3 (posterior condyle), and R6 (tibial diaphysis) at 12 months.
    1 context sentence
    Summary · context
    Twenty-two knees in 17 patients were included in this study, and a control group of patients who underwent TKA was identified according to their medical records.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients after knee arthroplasty, teriparatide increased adjusted tibial diaphysis BMD relative to controls at 12 months.

    In plain wordsIn patients after knee replacement, teriparatide increased tibial shaft bone density compared with controls at 12 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial diaphysis BMD at 12 months
    Study

    n: not reported in source

    Comparator
    TKA control group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, there was a significant increase in R2 (anterior condyle), R3 (posterior condyle), and R6 (tibial diaphysis) at 12 months.
    1 context sentence
    Summary · context
    Twenty-two knees in 17 patients were included in this study, and a control group of patients who underwent TKA was identified according to their medical records.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients after knee arthroplasty, the teriparatide group had higher adjusted BMD across all regions than controls at 6 and 12 months.

    In plain wordsIn patients after knee replacement, adjusted bone density was higher across all regions with teriparatide than controls.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseAdjusted BMD across all regions
    Study

    n: not reported in source

    Comparator
    TKA control group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The study group had a higher adjusted mean BMD in all regions than did the control group at 6 and 12 months.
    1 context sentence
    Summary · context
    Twenty-two knees in 17 patients were included in this study, and a control group of patients who underwent TKA was identified according to their medical records.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT04167163

Abaloparatide Before Total Knee Arthroplasty

University of Wisconsin, Madisonn = 5810 Jan 2020 to 3 Apr 2025

Osteoporosis · Arthroplasties, Knee Replacement

Trial pageClinicalTrials.govUpdated 5 Jun 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.